Current and former Tesla employees working in the company's open-air "tent" factory say they felt pressure to take shortcuts to hit aggressive Model 3 production goals,...Technologyread more
President Donald Trump and the RNC are picking up key supporters in the business community who did not back him as a candidate in 2016.2020 Electionsread more
Early Facebook investor and Trump supporter Peter Thiel weighed in on the Democrats taking on the president in 2020, saying he was "most scared' by Elizabeth Warren.Politicsread more
Tensions between Japan and South Korea come as the U.S. and its trading partners are embroiled in a global trade war.Technologyread more
The one-to-eight stock split would mean the current number of ordinary shares — which stands at 4 billion — will increase to 32 billion. It comes ahead of a reported Hong Kong...Asia Marketsread more
Treasury Secretary Steven Mnuchin is raising red flags ahead of Facebook's proposed cryptocurrency launch.Marketsread more
China's fiscal spending increased 10.7% in the first six months from a year earlier, the finance ministry said on Tuesday, underlining the government's bid to support the...China Economyread more
Beto O'Rourke's campaign for the 2020 election raised just $3.6 million in the second quarter of this year, putting him in the lower tier of candidates who have struggled to...2020 Electionsread more
Von der Leyen, one of the longest serving ministers in Germany, has tried to woo European lawmakers over the last two weeks.Europe Newsread more
The findings by McKinsey and Company come amid a year-long tariff fight between the U.S. and China, which has spilled into areas such as technology and security.China Economyread more
Microsoft's considerable reach into the corporate world isn't something Slack CEO Stewart Butterfield is very concerned about.Technologyread more
Notorious "pharma bro" Martin Shkreli has reached a settlement that "covers all outstanding disputes" with his former biopharmaceutical company Retrophin just weeks after he sued two company directors and its ex-general counsel from prison, Retrophin said Thursday.
Terms of the settlement were not disclosed. But Retrophin issued a statement to CNBC on Thursday when asked about Shkreli having filed a notice to dismiss on Tuesday of his recent lawsuit alleging fraud by the directors and ex-counsel.
"Retrophin and Martin Shkreli have reached a settlement resolving all outstanding disputes between them," a Retrophin spokeswoman said.
"We are pleased with this outcome and remain focused on delivering life-changing therapies to people living with rare diseases. Additional information about the settlement will be provided in Retrophin's forthcoming quarterly filing."
The spokeswoman confirmed that the settlement resolves not only Shkreli's latest suit, but also a legal action that Retrophin filed against him in August 2016 alleging that he had "breached his fiduciary duty of loyalty during his tenure as the Company's Chief Executive Officer and a member of its Board of Directors."
That action was pending in arbitration after Shkreli claimed it should be handled there instead of with a federal lawsuit, as Retrophin initially had called for.
Shkreli's latest suit had accused Retrophin's chairman of the board of directors, Gary Lyons; former company CEO Stephen Aselage, who currently is a director; and the firm's former top lawyer, Margaret Valeur-Jensen, of using fraud to oust him as head of the company in 2014.
Shkreli's lawsuit, which was filed in federal court in Manhattan on May 31, had sought damages of more than $30 million.
"After starting a biopharmaceutical company from scratch and turning it into a successful enterprise worth hundreds of millions of dollars, Mr. Shkreli was unceremoniously and illegally ousted from the company at the hands of Defendants," his suit had claimed.
On Tuesday, his lawyer filed notice that Shkreli's complaint was "voluntarily dismissed, with prejudice."
That means that Shkreli would be barred from refiling a suit of the same nature against the same defendants.
Shkreli's lawyer, Edward Kang, did not immediately respond to a request for comment.
The suit had been filed within days of Shkreli, 36, being transferred to a new prison in Pennsylvania.
He is serving a seven-year sentence for securities fraud related to his two defunct hedge funds and to Retrophin, which he founded after the funds financially collapsed.
Shkreli was convicted by a jury after a trial in August 2017 of three of eight criminal counts related to his hedge funds and to Retrophin. His release bond was revoked a month later when a judge said he was a danger to the public because of his offer on Facebook of a $5,000 bounty for samples of Hillary Clinton's hair.
The medication is used to treat a parasitic infection found in pregnant women, babies and HIV patients. Turing is now known as Phoenixus.
He had served his sentence at a low-security prison in Fort Dix, New Jersey. He was transferred to a federal jail in Brooklyn, New York, and then to Pennsylvania after The Wall Street Journal reported in March that he was still helping to "call the shots" at Phoenixus with the help of a contraband cellphone at Fort Dix.